Enzymatic Recognition of 2′‐Modified Ribonucleoside 5′‐Triphosphates: Towards the Evolution of Versatile Aptamers

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Standard

Enzymatic Recognition of 2′‐Modified Ribonucleoside 5′‐Triphosphates: Towards the Evolution of Versatile Aptamers. / Lauridsen, Lasse Holm; Rothnagel, Joseph A.; Veedu, Rakesh N.

In: ChemBioChem, Vol. 13, No. 1, 2012, p. 19-25.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Harvard

APA

CBE

MLA

Vancouver

Author

Lauridsen, Lasse Holm; Rothnagel, Joseph A.; Veedu, Rakesh N. / Enzymatic Recognition of 2′‐Modified Ribonucleoside 5′‐Triphosphates: Towards the Evolution of Versatile Aptamers.

In: ChemBioChem, Vol. 13, No. 1, 2012, p. 19-25.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Bibtex

@article{2da22acb87e747139caf359cf716a675,
title = "Enzymatic Recognition of 2′‐Modified Ribonucleoside 5′‐Triphosphates: Towards the Evolution of Versatile Aptamers",
keywords = "Aptamers, Polymerases, SELEX, Nucleotides",
publisher = "Wiley - V C H Verlag GmbH & Co. KGaA",
author = "Lauridsen, {Lasse Holm} and Rothnagel, {Joseph A.} and Veedu, {Rakesh N.}",
year = "2012",
doi = "10.1002/cbic.201100648",
volume = "13",
number = "1",
pages = "19--25",
journal = "ChemBioChem",
issn = "1439-4227",

}

RIS

TY - JOUR

T1 - Enzymatic Recognition of 2′‐Modified Ribonucleoside 5′‐Triphosphates: Towards the Evolution of Versatile Aptamers

A1 - Lauridsen,Lasse Holm

A1 - Rothnagel,Joseph A.

A1 - Veedu,Rakesh N.

AU - Lauridsen,Lasse Holm

AU - Rothnagel,Joseph A.

AU - Veedu,Rakesh N.

PB - Wiley - V C H Verlag GmbH & Co. KGaA

PY - 2012

Y1 - 2012

N2 - The quest for effective, selective and nontoxic nucleic‐acid‐based drugs has led to designing modifications of naturally occurring nucleosides. A number of modified nucleic acids have been made in the past decades in the hope that they would prove useful in target‐validation studies and therapeutic applications involving antisense, RNAi, aptamer, and ribozyme‐based technologies. Since their invention in the early 1990s, aptamers have emerged as a very promising class of therapeutics, with one drug entering the market for the treatment of age‐related macular degeneration. To combat the limitations of aptamers containing naturally occurring nucleotides, chemically modified nucleotides have to be used. In order to apply modified nucleotides in aptamer drug development, their enzyme‐recognition capabilities must be understood. For this purpose, several modified nucleoside 5′‐triphosphates were synthesized and investigated as substrates for various enzymes. Herein, we review studies on the enzyme‐recognition of various 2′‐sugar‐modified NTPs that were carried out with a view to their effective utilization in SELEX processes to generate versatile aptamers.

AB - The quest for effective, selective and nontoxic nucleic‐acid‐based drugs has led to designing modifications of naturally occurring nucleosides. A number of modified nucleic acids have been made in the past decades in the hope that they would prove useful in target‐validation studies and therapeutic applications involving antisense, RNAi, aptamer, and ribozyme‐based technologies. Since their invention in the early 1990s, aptamers have emerged as a very promising class of therapeutics, with one drug entering the market for the treatment of age‐related macular degeneration. To combat the limitations of aptamers containing naturally occurring nucleotides, chemically modified nucleotides have to be used. In order to apply modified nucleotides in aptamer drug development, their enzyme‐recognition capabilities must be understood. For this purpose, several modified nucleoside 5′‐triphosphates were synthesized and investigated as substrates for various enzymes. Herein, we review studies on the enzyme‐recognition of various 2′‐sugar‐modified NTPs that were carried out with a view to their effective utilization in SELEX processes to generate versatile aptamers.

KW - Aptamers

KW - Polymerases

KW - SELEX

KW - Nucleotides

U2 - 10.1002/cbic.201100648

DO - 10.1002/cbic.201100648

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

IS - 1

VL - 13

SP - 19

EP - 25

ER -